Feasibility of S-1 adjuvant chemotherapy after major hepatectomy for biliary tract cancers: An exploratory subset analysis of JCOG1202.

Major hepatectomy (MH) may produce the impaired liver function and affect the feasibility of adjuvant chemotherapy in terms of early period after the surgery, but there have not been detailed investigations. JCOG1202 (UMIN000011688) is a randomized phase III trial demonstrating the superiority of adjuvant S-1 chemotherapy for biliary tract cancer (BTC). The aim of this study is to examine the influence of MH for BTC on adjuvant S-1. Of the total 424 patients, 207 received S-1 (S-1 arm) while the remaining 217 were not. We compared MH with non-major hepatectomy (NMH) for BTC. In the S-1 arm, 42 had undergone MH, and 165 had undergone NMH. MH had similar pretreatment features to NMH, including the proportion of biliary reconstruction, to NMH, except for a lower platelet count (17.7 vs. 23.4 × 10 The treatment completion proportion and dose intensity were lower in MH than in NMH. Caution should be exercised against biliary tract infections and gastrointestinal disorders during adjuvant S-1 after MH for BTC.

Informations de copyright

© 2023 Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of competing interest MI has received grants from AstraZeneca, Bayer, Bristol-Myers Squibb, Chiome Bioscience, Chugai, Eisai, Eli Lilly Japan, Delta-Fly Pharma, Invitae, J-Pharma, Merck biopharma, Merus N.V., MSD, Novartis, Nihon Servier, Ono, Pfizer, Takeda, and Yakult; and honoraria from AstraZeneca, AbbVie, Abbott Japan, Bayer, Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly Japan, EA Pharma, Fujifilm Toyama Chemical, Incyte Biosciences Japan, MSD, Nihon Servier, Nippon Kayaku, Novartis, Otsuka, Teijin, Taiho, Taisho Pharmaceutical, Takeda, and Yakult. SH has received grant from Taiho Pharmaceutical. MU has received grants from Taiho Pharmaceutical, AstraZeneca, Merck Biopharma, Merck, Astellas Pharma, Eisai, Ono Pharmaceutical, Incyte Biosciences Japan, Chugai Pharmaceutical, Delta-Fly Pharma, and Daiich Sankyo and honoraria from Taiho Pharmaceutical, AstraZeneca, Merck Biopharma, Merck, NIHON SERVIER, Ono Pharmaceutical, Incyte Biosciences Japan, and Chugai Pharmaceutical. TO has received grants from AstraZeneca, Eisai, Merck, Syneos, EP-CRSU, Incyte Japan, and Dainippon Sumitomo Pharma; consulting fees from AstraZeneca, Eisai, Nihon Servier, FUJIFILM Toyama Chemical, Dainippon Sumitomo Pharma, and Bristol-Myers Squibb; and honoraria from AstraZeneca, Incyte Biosciences Japan, Eisai, Ono Pharmaceutical, Eli Lilly Japan, Yakult Honsha, Daiichi Sankyo, Taiho Pharmaceutical, Chugai Pharmaceutical, Teijin Pharma, Nippon Shinyaku, NIHON SERVIER, Novartis Pharma, Pfizer, and Mundipharma. JF has received grants from the National Cancer Center Research and Development Fund and Health, Labour Sciences Research Grants for Clinical Cancer Research, Ono Pharmaceutical, Merck, Merck Biopharma, J-Pharma, Taiho Pharmaceutical, Takeda, Chugai Pharma, AstraZeneca, Yakult Honsha, Eisai, Daiichi Sankyo, Mochida, Sanofi, Sumitomo Dainippon Bayer, Astellas, and Incyte Biosciences Japan; consulting fees from Fuji Film, Onco Therapy Science, Merck Biopharma, Ono Pharmaceutical, Merck, Taiho Pharmaceutical, Chugai Pharma, Astellas, AstraZeneca, Delta-Fly-Pharma, and Incyte Biosciences Japan; and honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Ono Pharmaceutical, Bayer, Eisai, Eli Lilly Japan, Merck, Yakult Honsha, Chugai Pharma, Novartis Pharma, AstraZeneca, Pfizer, Takeda, Taiho Pharmaceutical, EA Pharma, Daiichi Sankyo, Teijin Pharma, NIHON SERVIER, Terumo, and Incyte Biosciences Japan. All other authors declare no competing interests.